[go: up one dir, main page]

CO6331294A2 - Composiciones que contienen enzimas activables degradadoras de matriz - Google Patents

Composiciones que contienen enzimas activables degradadoras de matriz

Info

Publication number
CO6331294A2
CO6331294A2 CO10111097A CO10111097A CO6331294A2 CO 6331294 A2 CO6331294 A2 CO 6331294A2 CO 10111097 A CO10111097 A CO 10111097A CO 10111097 A CO10111097 A CO 10111097A CO 6331294 A2 CO6331294 A2 CO 6331294A2
Authority
CO
Colombia
Prior art keywords
enzymes
compositions containing
degrading enzymes
matrix degrading
ecm
Prior art date
Application number
CO10111097A
Other languages
English (en)
Inventor
Gilbert A Keller
Gregory Frost
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6331294(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Halozyme Inc filed Critical Halozyme Inc
Publication of CO6331294A2 publication Critical patent/CO6331294A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22015—Cathepsin L (3.4.22.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos y combinaciones para controlar la duración de acción, in vivo, de enzimas que degradan matriz. Los métodos y combinaciones permiten la activación in vivo temporal de las enzimas que degradan matriz durante la administración a la matriz extracelular (o "ECM"). Las enzimas que degradan matriz que tienen una duración controlada de acción pueden usarse para tratar enfermedades o trastornos mediados por ECM caracterizados al incrementar la deposición o acumulación de uno o más componentes ECM.
CO10111097A 2008-03-06 2010-09-08 Composiciones que contienen enzimas activables degradadoras de matriz CO6331294A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6866708P 2008-03-06 2008-03-06
US12772508P 2008-05-14 2008-05-14

Publications (1)

Publication Number Publication Date
CO6331294A2 true CO6331294A2 (es) 2011-10-20

Family

ID=41017153

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10111097A CO6331294A2 (es) 2008-03-06 2010-09-08 Composiciones que contienen enzimas activables degradadoras de matriz

Country Status (15)

Country Link
US (2) US9833498B2 (es)
EP (1) EP2274004B1 (es)
JP (2) JP5709531B2 (es)
KR (3) KR20100135779A (es)
AR (1) AR076627A1 (es)
AU (1) AU2009220094B2 (es)
BR (1) BRPI0909622A2 (es)
CA (1) CA2718549C (es)
CL (2) CL2009000541A1 (es)
CO (1) CO6331294A2 (es)
ES (1) ES2586765T3 (es)
IL (1) IL207293A (es)
MX (1) MX2010009806A (es)
TW (1) TWI395593B (es)
WO (1) WO2009111083A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058147A2 (en) 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
JP5649589B2 (ja) * 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
PL2580167T3 (pl) 2010-06-11 2022-11-21 Dvo, Inc. Układy i sposoby odzyskiwania składników odżywczych
CA2806058C (en) 2010-07-20 2016-09-13 Halozyme, Inc. Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
US8710014B2 (en) 2010-10-08 2014-04-29 Proteapex Therapeutics Llc Compositions and methods for inhibition of MMP13:MMP-substrate interactions
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
WO2012155212A1 (en) * 2011-05-18 2012-11-22 David Chin Method of treating excessive collagen formation
JP5860651B2 (ja) * 2011-09-30 2016-02-16 オリンパス株式会社 ホタル由来ルシフェラーゼ
FR2984129B1 (fr) * 2011-12-14 2014-01-10 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
FR2984130A1 (fr) * 2011-12-14 2013-06-21 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux vieillies ou senescentes.
FR2984128A1 (fr) * 2011-12-14 2013-06-21 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux sensibles.
FR2984127A1 (fr) * 2011-12-14 2013-06-21 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux grasses et/ou a tendance grasse.
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
US20150079069A1 (en) 2012-04-30 2015-03-19 Elastomics Ab Methods for modification of tissues
US20150196625A9 (en) * 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
WO2014172526A1 (en) * 2013-04-18 2014-10-23 Drexel University Novel methods of use of biomimetic proteoglycans
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
KR20160070077A (ko) 2013-10-03 2016-06-17 임프리미스 파마슈티컬스 인코포레이티드 안구내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조 방법
FI127924B (en) * 2014-02-27 2019-05-31 Oy Medix Biochemica Ab METHOD OF MEASURING MMP-8 ACTIVATION
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RS64397B1 (sr) 2015-03-27 2023-08-31 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003)
US10493247B2 (en) 2016-03-15 2019-12-03 Medtronic Holding Company Sàrl Devices for delivering a chemical denervation agent and methods of use
EP3503873A4 (en) 2016-08-25 2020-04-15 Harrow IP, LLC EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
US20210220449A1 (en) * 2018-05-15 2021-07-22 Translate Bio, Inc. Subcutaneous Delivery of Messenger RNA
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
JP7316647B2 (ja) * 2019-07-16 2023-07-28 日本メナード化粧品株式会社 カテプシンｖ活性促進剤及びｇａｔａ－３産生抑制剤
JP2022551086A (ja) * 2019-10-03 2022-12-07 ヴィトルヴィア ホールディングス インコーポレイテッド 結合組織修復の方法
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
EP4139448A1 (en) * 2020-04-20 2023-03-01 Pharmact Holding AG A modified bacterial hyaluronidase polypeptide, production process, pharmaceutical compositions and their uses
US11370973B2 (en) 2020-07-10 2022-06-28 Saudi Arabian Oil Company Processes and systems for producing one or more of benzene, toluene, or mixed xylenes
KR102486046B1 (ko) * 2020-12-14 2023-01-11 주식회사 뉴온바이오 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
CN115786302A (zh) * 2022-12-28 2023-03-14 无锡蔚蓝生物科技有限公司 脂肪酶突变体及其在白酒黄水处理中的应用

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539794A (en) 1967-09-12 1970-11-10 American Cyanamid Co Self-contained chemiluminescent lighting device
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
LU76148A1 (es) 1976-11-08 1978-07-10
SU787035A1 (ru) 1978-01-11 1980-12-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Устройство дл введени лекарственных препаратов
US4202314A (en) 1978-11-20 1980-05-13 Busygin Valery P Device for injection of medicinal preparations
JPS57128634A (en) 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
EP0072057B1 (en) 1981-08-10 1988-02-10 Duphar International Research B.V Automatic injection syringe
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4687610A (en) 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
SE457417B (sv) 1987-04-14 1988-12-27 Astra Meditec Ab Automatisk tvaakammarspruta, foerfarande foer blandning och injicering med sprutan samt ampull foer tvaakammarspruta
GB2205643B (en) 1987-05-08 1991-03-13 Farmos Group Limited Type iii collagen degradation assay
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5051449A (en) 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
GB9105893D0 (en) 1991-03-20 1991-05-08 Orion Yhtymae Oy Bone resorption assay based on a peptide liberated during collagen degradation
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5171081A (en) 1992-05-29 1992-12-15 Pita Joe W Chemiluminescent reactive vessel
JPH0775573A (ja) * 1992-06-19 1995-03-20 Takeda Chem Ind Ltd ヒトカテプシンの製造法および該酵素含有製剤
CA2098777A1 (en) 1992-06-19 1993-12-20 Yukio Fujisawa Production of human cathepsin and its use
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JPH06192124A (ja) * 1992-12-25 1994-07-12 Toray Ind Inc 血液細胞増加剤
US5353961A (en) 1993-01-15 1994-10-11 Reseal International Limited Partnership Dual chamber dispenser
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
GB9319103D0 (en) 1993-09-15 1993-11-03 Unilever Plc Skin care method & composition
US5395326A (en) 1993-10-20 1995-03-07 Habley Medical Technology Corporation Pharmaceutical storage and mixing syringe having high pressure assisted discharge
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6114159A (en) 1994-03-17 2000-09-05 Max-Delbruck-Centrum Fur Molekulare Medizin DNA sequences for matrix metalloproteases, their production and use
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
JP2996415B2 (ja) 1994-03-31 1999-12-27 アムジエン・インコーポレーテツド 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6544767B1 (en) * 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
DE4445969C1 (de) 1994-12-22 1996-03-14 Schott Glaswerke Spritzenzylinder für eine Zweikammer-Fertigspritze, Zweikammer-Fertigspritze und Verfahren zum Herstellen und Füllen derselben
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5523090A (en) 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
US5536499A (en) 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US6461378B1 (en) 1995-05-05 2002-10-08 Thermage, Inc. Apparatus for smoothing contour irregularities of skin surface
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5705170A (en) 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5747322A (en) 1996-05-09 1998-05-05 The Regents Of The University Of California Recombinant crab collagenase
US5976556A (en) 1996-06-13 1999-11-02 Active Organics, Inc. Combination of acid protease enzymes and acidic buffers and uses thereof
US5667793A (en) 1996-08-02 1997-09-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions for treating cellulite
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US5776759A (en) * 1996-09-26 1998-07-07 Incyte Pharmaceuticals, Inc. Two novel human cathepsin proteins
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6071526A (en) 1997-03-27 2000-06-06 S.W. Patentverwertungs Ges M.B. H. Cosmetic or cosmetic product for firming and soothing the skin in particular in the case of cellulite
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
AU8513198A (en) 1997-07-25 1999-02-16 Du Pont Pharmaceuticals Company Aggrecan degrading metallo proteases
FR2767833B1 (fr) 1997-08-29 2001-03-02 Oreal Polypeptide isole de l'epiderme et son utilisation
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6153207A (en) 1998-03-05 2000-11-28 Pugliese; Peter T. Anti-cellulite pantyhose
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
JP2002506801A (ja) 1998-03-16 2002-03-05 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳類の皮膚のセルライトを軽減する方法
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2002519686A (ja) 1998-07-03 2002-07-02 ネレス・フィールド・コントロールズ・オイ 液体物質測定方法および装置
US6031005A (en) 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6443914B1 (en) 1998-08-10 2002-09-03 Lysonix, Inc. Apparatus and method for preventing and treating cellulite
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6060474A (en) 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
EP1150699A4 (en) 1999-02-01 2004-06-30 John Lezdey TREATMENT OF BLADDER AND GASTROINTESTINAL MASTO CYTOSIS
ES2209877T3 (es) * 1999-04-29 2004-07-01 Ista Pharmaceuticals, Inc Uso de una hialuronidasa determinada para eliminar las cicatrices, las opacidades y las nubeculas corneales.
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6656701B2 (en) 1999-07-16 2003-12-02 Actim Organics, Inc Combination of acid protease enzymes and acidic buffers and uses thereof
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
AU6918700A (en) 1999-08-20 2001-03-19 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
CA2395902A1 (en) 1999-12-28 2001-07-05 Asger Lau Dalmose Dual chamber syringe with a dual function piston
US20030212021A1 (en) 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
GB2375965B (en) 2000-01-28 2004-09-01 Novo Nordisk As A dose setting limiter
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
US6620592B2 (en) * 2000-02-28 2003-09-16 Millennium Pharmaceuticals, Inc. 18036, a novel calpain-like protease and uses thereof
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2003532678A (ja) 2000-05-12 2003-11-05 ノバラー ファーマシューティカルズ， インコーポレイテッド 局所麻酔の方法およびキット
JP4873818B2 (ja) 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
US20020106388A1 (en) 2000-11-24 2002-08-08 Pugliese Peter T. Formulation of flavones and isoflavones for treatment of cellulite
WO2002049673A2 (en) 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US20040146494A1 (en) * 2001-04-06 2004-07-29 Santana Cristiano Alberto Ribeiro Papaine containing pharmaceutical formulation resp its use
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP4758608B2 (ja) 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
US6972005B2 (en) 2002-05-10 2005-12-06 Boehm Jr Frank H Dual chamber syringe and dual lumen needle
US6682904B1 (en) 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
WO2004058147A2 (en) * 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2572733A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
NZ541374A (en) 2003-05-23 2008-09-26 Nektar Therapeutics Al Corp PEG derivatives having an amidocarbonate linkage
WO2005016227A2 (en) 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
US7572613B2 (en) 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
PT1896401E (pt) 2005-02-25 2013-07-17 Univ Temple Síntese de sulfuretos, sulfonas, sulfóxidos e sulfonamidas não saturados
CA2612768A1 (en) 2005-06-30 2007-01-11 Mallinckrodt Inc. Dual chamber syringe
US20070004036A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070003541A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070128685A1 (en) 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US20080131500A1 (en) 2006-12-04 2008-06-05 The Board Of Regents Of The University Of Texas System Methods and compositions for rapid inactivation of proteins
PT4269578T (pt) 2008-03-06 2024-06-18 Halozyme Inc Produção em grande escala de hialuronidase solúvel
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
JP5649589B2 (ja) 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
KR20110136825A (ko) 2009-03-09 2011-12-21 바이오아트라, 엘엘씨 미락 단백질
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法

Also Published As

Publication number Publication date
EP2274004B1 (en) 2016-06-01
US20140271609A1 (en) 2014-09-18
AU2009220094B2 (en) 2013-11-07
KR20160073346A (ko) 2016-06-24
BRPI0909622A2 (pt) 2019-09-24
AR076627A1 (es) 2011-06-29
IL207293A (en) 2016-12-29
EP2274004A2 (en) 2011-01-19
JP2014043449A (ja) 2014-03-13
TWI395593B (zh) 2013-05-11
TW200944227A (en) 2009-11-01
WO2009111083A3 (en) 2010-03-25
HK1150554A1 (zh) 2012-01-06
CL2013002070A1 (es) 2013-11-15
CL2009000541A1 (es) 2009-10-09
MX2010009806A (es) 2010-11-30
AU2009220094A1 (en) 2009-09-11
JP2011517318A (ja) 2011-06-02
CA2718549C (en) 2016-08-09
US9775889B2 (en) 2017-10-03
KR20130106893A (ko) 2013-09-30
JP5709531B2 (ja) 2015-04-30
IL207293A0 (en) 2010-12-30
US9833498B2 (en) 2017-12-05
US20100003237A1 (en) 2010-01-07
WO2009111083A2 (en) 2009-09-11
KR101647933B1 (ko) 2016-08-11
CA2718549A1 (en) 2009-09-11
KR20100135779A (ko) 2010-12-27
ES2586765T3 (es) 2016-10-18

Similar Documents

Publication Publication Date Title
CO6331294A2 (es) Composiciones que contienen enzimas activables degradadoras de matriz
MX2009004365A (es) Dispositivos oculares y metodos para la fabricacion y uso de los mismos.
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DE602007006815D1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxyü-piperidin-1-carbonsäure isopropyl ester als stoffwechselmodulatore und behandlung von damit assoziierten erkrankungen
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
UY30732A1 (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008067403A3 (en) Presbyopia treatment by lens alteration
EA201490613A1 (ru) Соединения с замедляющим старение действием
MX389018B (es) Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
CL2011001428A1 (es) Compuestos derivados de amidas del acido tetrahidroisoquinolil-4-oxobutirico; composicion farmaceutica; y uso en el tratamiento de desordenes o enfermedades mediadas por canales de potasio kcnq2/3, tales como dolor, epilepsia. incontinencia urinaria, ansiedad, entre otras.
AR066312A1 (es) Uso de glucoproteinas de mucina en combinacion con agentes terapeuticos para tratar lesiones epiteliales y trastornos por deterioro de la funcion de la mucina
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
RU2009118942A (ru) Способ стимуляции регенерации тканей
DK1982696T3 (da) Gel til behandling af sår
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
EP2253206A4 (en) COMPOSITION FOR COMBATING PLANT DISEASES
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
CR20110010A (es) Formulaciones que tienen una compatibilidad mejorada con sustratos no tejidos

Legal Events

Date Code Title Description
FC Application refused